AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia

Cong Li(Tianjin Stomatological Hospital), Kang Dai(Amgen (United States)), Alexander Kamb(Integrated BioTherapeutics (United States)), Katie Newhall(Immunome (United States)), Angus M. Sinclair(LabGenius (United Kingdom)), Dineli Wickramasinghe(Amgen (United States)), Zhihong Li(Central South University), Zhen Xia(Amgen (United States)), Lingming Liang(Amgen (United States)), Lawrence R. McGee(Amgen (United States)), Xianghong Wang(Hebei Agricultural University), Liqin Liu(Xinjiang Agricultural University)
Molecular Cancer Therapeutics
December 9, 2014
Cited by 38


Related Papers